Trial Profile
A randomized, 30 week, active-controlled, open-label, 3-treatment arm, parallel-group multicenter study comparing the efficacy and safety of insulin glargine/ lixisenatide fixed ratio combination to insulin glargine alone and to lixisenatide alone on top of metformin in patients with Type 2 diabetes mellitus
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin glargine; Lixisenatide; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms LixiLan-O
- Sponsors Sanofi
- 22 Feb 2024 Results of pooled analysis of four studies (LixiLan-O, LixiLan-G, LixiLan-L, SoliMix) assessing efficacy and safety of iGlarLixi in older people (≥65 years) with type 2 diabetes (T2D) advancing or switching from oral agents, published in the Diabetes, Obesity and Metabolism
- 26 Jun 2023 Results of a post-hoc pooled analysis assessing factors associated with achieving target HbA1c <7.0% in people with type 2 diabetes treated with iGlarLixi from four clinical trials: NCT02058147, NCT02058160, NCT02787551 and EudraCT2017-003370-13 presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 26 Jun 2023 Results (n=465) of a post-hoc pooled analysis assessing predictors of glycemic control in older people with type 2 diabetes treated with iGlarLixi from following clinical trials: NCT02058147, NCT02058160, NCT02787551 and EudraCT2017-003370-13 presented at the 83rd Annual Scientific Sessions of the American Diabetes Association